Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate cell- and tissue-based platforms for assessing potential adverse biological consequences of somatic cell genome editing.

This opportunity supports research opportunities that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.  

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications proposing research on the development of novel and optimized alternatives to existing in vivo genome editing complexes.

This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

This initiative will support exploratory projects that exploit HIV or host genomic or nucleomic information to understand HIV latency in individuals with substance use disorders (SUDs).

The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.

This Administrative Supplement Program intends to support gene function studies in collaboration with the NIH Undiagnosed Diseases Program (UDP) to investigate the underlying genetics, biochemistry and pathophysiology of newly diagnosed diseases identified through the UDP. In recent years, gene function studies combined with genetic and genomic analyses and metabolic studies have greatly improved diagnoses of these very rare diseases and advanced scientific knowledge of the underlying pathogenesis. This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund), invites applications to support bioinformatics research training programs at low or middle income (LMIC) African country institutions with significant genomics research capacity.  African applicants may propose graduate degree and long term postdoctoral bioinformatics research training in collaboration with other African or high income country (HIC) collaborators.  It is expected that these training programs will address the need for bioinformatics research expertise in the H3Africa Consortium and result in sustainable centers of bioinformatics research training relevant to global health research for the African continent.

The purpose of this FOA is to solicit applications from foreign institutions in African countries to provide an Administrative Coordinating Center for the H3Africa Consortium.  H3Africa research projects employ state of the art genomics approaches to study genetic and environmental contributors to specific health condition(s) or disease(s) relevant to African populations. The H3Africa Administrative Coordinating Center will provide the organizational framework for the management, direction, and overall coordination of all common H3Africa activities (i.e. Consortium activities). 

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from foreign Institutions in African countries.  The purpose of this FOA is to call for applications for investigator-initiated H3Africa Research Projects.  An H3Africa Research Project is a discrete, specified, circumscribed research project, conducted by a single investigator or multiple investigators, that employs state-of-the-art genomics approaches and relates to the study of genetic and/or environmental contributors to specific health condition(s) or disease(s) relevant to African populations.  

The purpose of this FOA is to both expand existing, as well as  develop novel, capabilities for capacity building and implementation related to genomic research on the African continent by providing support for an Informatics Network for the Human Heredity and Health in Africa (H3Africa) Consortium.

This Funding Opportunity Announcement (FOA) encourages applications to study the ethical, legal and societal issues (ELSI) of human genome research in African populations.  Of particular interest are projects that propose focused bioethical, legal, and social science analyses of new or emerging issues. 

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from foreign Institutions in African countries to submit applications for H3Africa Collaborative Centers.  These awards will support 3-5 collaborating research projects at three or more African institutions working together as a partnership to accomplish more than each project could accomplish on its own.  An H3Africa Collaborative Center should employ state of the art genomics approaches to study genetic and environmental contributors to specific health condition(s) or disease(s) relevant to African populations.

The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).

The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).

The National Institute on Alcohol Abuse and Alcoholism is publishing a Funding Opportunity Announcement (FOA) to seek applications on novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders are complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol.